Biomarkers for wound healing

• US 8,034,553 B2
• Filed: 06/24/2004
• Issued: 10/11/2011
• Est. Priority Date: 06/24/2004
• Status: Expired due to Fees

• Current Assignee: Avent Incorporated (Avanos Medical, Inc.)
• Original Assignee: Kimberly-Clark Worldwide Incorporated (Kimberly-Clark Corporation)
• Inventors: McGrath, Kevin P.
• Primary Examiner(s): DUNSTON, JENNIFER ANN
• Application Number:
  US10/876,787
• Publication Number:
  US 20050287535A1
• Time in Patent Office: 2,665 Days
• Field of Search: None
• US Class Current: N/A
• CPC Class Codes: G01N 2333/545 IL-1
• CPC Class Codes: G01N 2500/04 Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
• CPC Class Codes: G01N 33/6869 Interleukin
• CPC Class Codes: G01N 33/6887 from muscle, cartilage or connective tissue

Abstract

The invention relates to the discovery that in chronic wounds the expression levels of certain genes are altered relative to the expression levels observed in healthy tissues.

Claims

1. A method comprising

quantifying expression levels of one or more genes in a wound tissue sample from a wound of a mammalian subject, the wound being at least 7 days old, the one or more genes consisting of one or more of angiotensin II receptor, interleukin I receptor antagonist or inositol triphosphate receptor 3, the expression level being quantified by highly stringent hybridization of RNA obtained from the wound tissue sample to a probe that is complementary to SEQ ID NO:

1, SEQ ID NO;

3 or SEQ ID NO;

5, wherein the only gene expression levels quantified in the method are one or more of angiotensin II receptor, interleukin I receptor antagonist and inositol triphosphate receptor 3, and wherein the expression level of inositol triphosphate receptor 3 is quantified; and

comparing the expression level of the angiotensin II receptor, interleukin I receptor antagonist or inositol triphosphate receptor 3 of the wound tissue sample with another expression level of angiotensin II receptor, interleukin I receptor antagonist or inositol triphosphate receptor 3 in tissue of the same type from the mammalian subject.

2. The method of claim 1, wherein the mammalian subject is a human subject.

3. The method of claim 1, wherein the hybridization comprises hybridization of the wound tissue sample RNA to an array of probes complementary to SEQ ID NO:

5.

4. The method of claim 3, wherein the hybridization further comprises hybridization of the wound tissue sample RNA to an array of probes complementary to SEQ ID NO:

1 or SEQ ID NO;

3.

5. The method of claim 1, wherein the hybridization comprises hybridization of a northern blot of the wound tissue sample RNA to probes complementary to SEQ ID NO:

5.

6. The method of claim 5, wherein the hybridization further comprises hybridization of a northern blot of the wound tissue sample RNA to probes complementary to SEQ ID NO:

1 or SEQ ID NO;

3.

7. A method comprising

quantifying expression levels of genes in a wound tissue sample from a wound of a mammalian subject, the wound being at least 7 days old, the genes consisting of angiotensin II receptor, interleukin I receptor antagonist, and inositol triphosphate receptor 3, the expression level being quantified by highly stringent hybridization of RNA obtained from the wound tissue sample to probes that are complementary to SEQ ID NO:

1, SEQ ID NO;

3 and SEQ ID NO;

5, wherein the only gene expression levels quantified in the method are angiotensin II receptor, interleukin I receptor antagonist and inositol triphosphate receptor 3, and

comparing the expression level of the angiotensin II receptor, interleukin I receptor antagonist and inositol triphosphate receptor 3 of the wound tissue sample with another expression level of angiotensin II receptor, interleukin I receptor antagonist and inositol triphosphate receptor 3 in tissue of the same type from the mammalian subject.

8. A method comprising

quantifying expression levels of one or more genes in a wound tissue sample from a wound of a mammalian subject, the wound being at least 7 days old, the one or more genes consisting of angiotensin II receptor, interleukin I receptor antagonist or inositol triphosphate receptor 3, the expression level being quantified by amplification of RNA obtained from the wound tissue sample using primers complementary to, and that selectively hybridize to, SEQ ID NO:

1, SEQ ID NO;

3 or SEQ ID NO;

5, wherein the only gene expression levels quantified in the method are one or more of angiotensin II receptor, interleukin I receptor antagonist and inositol triphosphate receptor 3, and wherein the expression level of inositol triphosphate receptor 3 is quantified, and

comparing the expression level of the angiotensin II receptor, interleukin I receptor antagonist or inositol triphosphate receptor 3 of the wound tissue sample with another expression level of angiotensin II receptor, interleukin I receptor antagonist or inositol triphosphate receptor 3 in tissue of the same type from the mammalian subject.

9. A method comprising

obtaining a tissue biopsy from a wound tissue, the wound tissue being from a wound that is at least 7 days old;

homogenizing the tissue biopsy;

extracting mRNA from the homogenized tissue biopsy;

hybridizing the mRNA to a probe that is complementary to SEQ ID NO;

1, SEQ ID NO;

3, or SEQ ID NO;

5, wherein the mRNA is hybridized to the probe under highly stringent hybridization conditions; and

quantifying the expression levels of one or more genes in the wound tissue, the one or more genes consisting of angiotensin II receptor, interleukin I receptor antagonist or inositol triphosphate receptor 3, wherein the only expression levels quantified in the method are one or more of angiotensin II receptor, interleukin I receptor antagonist or inositol triphosphate receptor 3, and wherein the expression level of inositol triphosphate receptor 3 is quantified.

10. The method of claim 9, wherein the wound tissue is from a mammalian subject.

11. The method of claim 10, wherein the mammalian subject is a human subject.

12. The method of claim 9, wherein the hybridization comprises hybridization of the wound tissue sample RNA to an array of probes complementary to SEQ ID NO:

5.

13. The method of claim 12, wherein the hybridization further comprises hybridization of the wound tissue sample RNA to an array of probes complementary to SEQ ID NO:

1 or SEQ ID NO;

3.

14. The method of claim 9, wherein the hybridization comprises hybridization of a northern blot of the wound tissue sample RNA to probes complementary to SEQ ID NO:

5.

15. The method of claim 14, wherein the hybridization further comprises hybridization of a northern blot of the wound tissue sample RNA to probes complementary to SEQ ID NO:

1 or SEQ ID NO;

3.

16. A method comprising

obtaining a tissue biopsy from a wound tissue, the wound tissue being from a wound that is at least 7 days old;

homogenizing the tissue biopsy;

extracting mRNA from the homogenized tissue biopsy;

hybridizing the mRNA to probes that are complementary to SEQ ID NO;

1, SEQ ID NO;

3, and SEQ ID NO;

5, wherein the mRNA is hybridized to the probes under highly stringent hybridization conditions; and

quantifying expression levels of genes in the wound tissue, the genes consisting of angiotensin II receptor, interleukin I receptor antagonist, and inositol triphosphate receptor 3, wherein the only expression levels quantified in the method are angiotensin II receptor, interleukin I receptor antagonist and inositol triphosphate receptor 3.

17. A method comprising

obtaining a tissue biopsy from a wound tissue, the wound tissue being from a wound that is at least 7 days old;

homogenizing the tissue biopsy;

extracting mRNA from the homogenized tissue biopsy;

amplifying the mRNA obtained from the wound using primers that are complementary to SEQ ID NO;

1, SEQ ID NO;

3, or SEQ ID NO;

5, wherein the primers selectively hybridize to SEQ ID NO;

1, SEQ ID NO;

3, or SEQ ID NO;

5; and

quantifying expression levels of one or more genes in the wound tissue, the one or more genes consisting of angiotensin II receptor, interleukin I receptor antagonist or inositol triphosphate receptor 3, wherein the only expression revels quantified in the method are one or more of angiotensin II receptor, interleukin I receptor antagonist and inositol triphosphate receptor 3, and wherein the expression level of inositol triphosphate receptor 3 is quantified.